ARTICLE | Company News
Curalogic inflammation, autoimmune news
December 8, 2008 8:00 AM UTC
Curalogic's board recommended the liquidation of the company's assets to its shareholders after it was unable to secure a partner for external development projects. In January, Curalogic reduced headcount and discontinued development of all its programs, including its Phase III vaccines for grass and ragweed allergies, to seek new development projects with external partners. ...